Skip to main content
Clinical Trials/IRCT20161207031288N6
IRCT20161207031288N6
Recruiting
Phase 2

consideration of clinical safety and efficacy of topical formulation of polyphenolic extract of punica granatum on patients with mild to moderate forms of melasma

Tehran University of Medical Sciences0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
20
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Mild to moderate melasma with minimum grade of Melasma area and severity index \= 1
  • Age range 18\-50
  • Signing consent form, voluntarily and knowingly

Exclusion Criteria

  • Pregnancy or lactation
  • Using oral corticosteroids or isotretinoin within 28 days prior to the study
  • Any active skin disease at test area including rosacea, eczema, atrophy, acne
  • Using any light sensitizing medicine within 3 months prior to the study
  • Use of topical lightening products like alpha hydroxy acid, beta hydroxy acid, and retinoid component within 21 days prior to the study
  • Documented allergy to components of the cream
  • History of laser treatment or dermabrasion or deep facial peeling within the past 3 months prior to the study
  • Using contraceptive or hormonal medicines

Outcomes

Primary Outcomes

Not specified

Similar Trials